Chu Pauling, Chao Tsu-Yi, Lin Yuh-Feng, Janckila Anthony J, Yam Lung T
Division of Nephrology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Am J Kidney Dis. 2003 May;41(5):1052-9. doi: 10.1016/s0272-6386(03)00203-8.
Serum tartrate-resistant acid phosphatase 5b (TRACP) is a new marker of potential clinical use to monitor osteoclastic activity and bone resorption rate. The relationship between histomorphometric parameters of bone resorption and serum TRACP was evaluated in 14 chronically dialyzed patients and 6 healthy control subjects.
All patients underwent bone biopsies and serum biochemical testing for TRACP, intact parathyroid hormone (iPTH), pyridinoline cross-linked telopeptide domain of type I collagen (ICTP), total calcium, phosphorus, and albumin, which were measured at the time of biopsy.
Bone histological examination showed predominant hyperparathyroid bone disease (HPT) in 6 patients, mixed uremic osteodystrophy in 3 patients, low-turnover osteomalacia in 1 patient, and adynamic bone disease in 4 patients. Mean TRACP activity was 3.25 +/- 0.59 U/L in control subjects. Median TRACP activity was significantly greater in patients with HPT (11.97 +/- 8.92 U/L) than those with other types of renal osteodystrophy (ROD; 2.17 +/- 0.61 U/L). Serum iPTH levels were greatest in all patients with HPT, but also were significantly elevated in 7 of 8 patients with other types of ROD. Serum ICTP levels also were significantly elevated in all patients with HPT and 6 of 8 patients with other types of ROD. Serum TRACP levels correlated more strongly with histological parameters of osteoclasts than those of erosion. Also, correlations between TRACP and histological parameters of osteoclasts were stronger than those of iPTH and ICTP levels.
These early results suggest that serum TRACP levels correlate well with histological indices of osteoclasts and may serve as a specific marker for osteoclastic activity in patients with renal bone disease.
血清抗酒石酸酸性磷酸酶5b(TRACP)是一种具有潜在临床应用价值的新标志物,可用于监测破骨细胞活性和骨吸收速率。在14例长期透析患者和6例健康对照者中评估了骨吸收组织形态计量学参数与血清TRACP之间的关系。
所有患者均接受了骨活检以及血清TRACP、完整甲状旁腺激素(iPTH)、I型胶原吡啶啉交联端肽结构域(ICTP)、总钙、磷和白蛋白的生化检测,这些指标在活检时进行测量。
骨组织学检查显示,6例患者主要为甲状旁腺功能亢进性骨病(HPT),3例患者为混合性尿毒症骨营养不良,1例患者为低转换型骨软化症,4例患者为动力缺乏型骨病。对照组的平均TRACP活性为3.25±0.59 U/L。HPT患者的TRACP活性中位数(11.97±8.92 U/L)显著高于其他类型肾性骨营养不良(ROD)患者(2.17±0.61 U/L)。所有HPT患者的血清iPTH水平最高,但其他类型ROD的8例患者中有7例也显著升高。所有HPT患者以及其他类型ROD的8例患者中有6例的血清ICTP水平也显著升高。血清TRACP水平与破骨细胞组织学参数的相关性比与侵蚀参数的相关性更强。此外,TRACP与破骨细胞组织学参数之间的相关性比iPTH和ICTP水平之间的相关性更强。
这些早期结果表明,血清TRACP水平与破骨细胞组织学指标密切相关,可能作为肾性骨病患者破骨细胞活性的特异性标志物。